Ali Ezzati1, Richard B Lipton1. 1. Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
Abstract
BACKGROUND: The ideal participants for Alzheimer's disease (AD) clinical trials would show cognitive decline in the absence of treatment (i.e., placebo arm) and also would be responsive to the therapeutic intervention being studied (i.e., drug arm). One strategy to boost the power of trials is to enroll individuals who are more likely to progress targeted using data-driven predictive models. OBJECTIVE: To investigate if machine learning (ML) models can effectively predict clinical disease progression (cognitive decline) in mild-to-moderate AD patients during the timeframe of a phase III clinical trial. METHODS: Data from 202 participants with a diagnosis of AD at baseline from the Alzheimer's Disease Neuroimaging Initiative (ADNI) was used to train ML classifiers that can differentiate between individuals who had declining cognitive function (DC) and individuals with stable cognitive function (SC). DC was defined as any downward change in the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) score over 12 months of follow-up. SC was defined by the absence of decline in ADAS-cog. Trained models were applied to data from 77 participants from the placebo arm of the phase III trial of Semagacestat (LFAN study) to identify subgroups of SC versus DC. RESULTS: Only 74.8% of ADNI participants and 63.6% of LFAN participants had cognitive decline after one year of follow up. K-nearest neighbors (kNN) classifier had an accuracy of 68.3%, sensitivity of 80.1%, and specificity of 33.3% for identifying decliners in ADNI (training sample). In LFAN (validation sample), the model showed an overall accuracy of 61.3%, sensitivity of 65.5%, and specificity of 47.0% in identifying decliners at the 12 months of follow-up. The model had a positive predictive value of 80.8%, which was 17.2% more than the base prevalence of decliners. CONCLUSIONS: Machine learning predictive models can be effectively used to boost the power of clinical trials by reducing the sample size.
RCT Entities:
BACKGROUND: The ideal participants for Alzheimer's disease (AD) clinical trials would show cognitive decline in the absence of treatment (i.e., placebo arm) and also would be responsive to the therapeutic intervention being studied (i.e., drug arm). One strategy to boost the power of trials is to enroll individuals who are more likely to progress targeted using data-driven predictive models. OBJECTIVE: To investigate if machine learning (ML) models can effectively predict clinical disease progression (cognitive decline) in mild-to-moderate ADpatients during the timeframe of a phase III clinical trial. METHODS: Data from 202 participants with a diagnosis of AD at baseline from the Alzheimer's Disease Neuroimaging Initiative (ADNI) was used to train ML classifiers that can differentiate between individuals who had declining cognitive function (DC) and individuals with stable cognitive function (SC). DC was defined as any downward change in the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) score over 12 months of follow-up. SC was defined by the absence of decline in ADAS-cog. Trained models were applied to data from 77 participants from the placebo arm of the phase III trial of Semagacestat (LFAN study) to identify subgroups of SC versus DC. RESULTS: Only 74.8% of ADNIparticipants and 63.6% of LFAN participants had cognitive decline after one year of follow up. K-nearest neighbors (kNN) classifier had an accuracy of 68.3%, sensitivity of 80.1%, and specificity of 33.3% for identifying decliners in ADNI (training sample). In LFAN (validation sample), the model showed an overall accuracy of 61.3%, sensitivity of 65.5%, and specificity of 47.0% in identifying decliners at the 12 months of follow-up. The model had a positive predictive value of 80.8%, which was 17.2% more than the base prevalence of decliners. CONCLUSIONS: Machine learning predictive models can be effectively used to boost the power of clinical trials by reducing the sample size.
Authors: Andrea R Zammit; Graciela Muniz-Terrera; Mindy J Katz; Charles B Hall; Ali Ezzati; David A Bennett; Richard B Lipton Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson Journal: Nat Rev Neurol Date: 2010-02 Impact factor: 42.937
Authors: R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal Journal: Alzheimer Dis Assoc Disord Date: 1997 Impact factor: 2.703
Authors: Lawrence S Honig; Bruno Vellas; Michael Woodward; Mercè Boada; Roger Bullock; Michael Borrie; Klaus Hager; Niels Andreasen; Elio Scarpini; Hong Liu-Seifert; Michael Case; Robert A Dean; Ann Hake; Karen Sundell; Vicki Poole Hoffmann; Christopher Carlson; Rashna Khanna; Mark Mintun; Ronald DeMattos; Katherine J Selzler; Eric Siemers Journal: N Engl J Med Date: 2018-01-25 Impact factor: 91.245
Authors: Ali Ezzati; Andrea R Zammit; Danielle J Harvey; Christian Habeck; Charles B Hall; Richard B Lipton Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Andrea R Zammit; Charles B Hall; Mindy J Katz; Graciela Muniz-Terrera; Ali Ezzati; David A Bennett; Richard B Lipton Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Jared F Benge; Steve Balsis; Lisa Geraci; Paul J Massman; Rachelle S Doody Journal: Dement Geriatr Cogn Disord Date: 2009-07-30 Impact factor: 2.959
Authors: Vladimir Coric; Stephen Salloway; Christopher H van Dyck; Bruno Dubois; Niels Andreasen; Mark Brody; Craig Curtis; Hilkka Soininen; Stephen Thein; Thomas Shiovitz; Gary Pilcher; Steven Ferris; Susan Colby; Wendy Kerselaers; Randy Dockens; Holly Soares; Stephen Kaplita; Feng Luo; Chahin Pachai; Luc Bracoud; Mark Mintun; Joshua D Grill; Ken Marek; John Seibyl; Jesse M Cedarbaum; Charles Albright; Howard H Feldman; Robert M Berman Journal: JAMA Neurol Date: 2015-11 Impact factor: 18.302
Authors: Ali Ezzati; Ahmed Abdulkadir; Clifford R Jack; Paul M Thompson; Danielle J Harvey; Monica Truelove-Hill; Lasya P Sreepada; Christos Davatzikos; Richard B Lipton Journal: Alzheimers Dement Date: 2021-11-10 Impact factor: 21.566
Authors: Ali Ezzati; Christos Davatzikos; David A Wolk; Charles B Hall; Christian Habeck; Richard B Lipton Journal: Alzheimers Dement (N Y) Date: 2022-03-14
Authors: Charles F Murchison; Byron C Jaeger; Jeff M Szychowski; Gary R Cutter; Erik D Roberson; Richard E Kennedy Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160